Drugs / RO5093151
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT02622334 | Dec 2015 → Jul 2016 | glaucoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01591850 | Sep → Nov 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01277094 | Apr 2011 → Mar 2012 | NAFLD1 | Hoffmann-La Roche | Completed | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT01493271 | Dec 2011 → Nov 2012 | open-angle glaucoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00823680 | Apr → Aug 2009 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO5093151 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01277094 ↗ |
| Action | Inhibit | “Inhibition of 11β-HSD1 by RO5093151 was effective and safe in reducing liver-fat content” PMID 24795254 ↗ Feb 2014 |
| Route | Oral | “400mg po bid for 4 weeks” NCT00823680 ↗ |